2020更新
2020更新
|
1. 中心近年舉辦研習活動名稱及參與人數
本中心共舉辦8場學術研討會,共計973人次參加。
日期 |
活動名稱 |
參與人數 |
103.10.24 |
台俄雙邊研討會-海洋天然化合物於生物醫學之應用 |
40人 |
103.12.22 |
高雄醫學大學與北京首都醫科大學學術交流會-奈米藥物於腫瘤、血栓、骨質疏鬆之生醫與產業應用-彭師奇教授 |
40人 |
104.12.27 |
先進生物醫學應用研討會 |
200人 |
104.02.04 |
Seattle Genetics, Inc.至生物標記暨生技藥物研究中心進行學術交流。 |
50人 |
105.11.19 |
台灣基因醫學暨生物標記學會年會 |
205人 |
106.11.18 |
台灣基因醫學暨生物標記學會年會 |
200人 |
107.11.10 |
台灣基因醫學暨生物標記學會年會暨精準醫療應用研討會 |
208 人 |
107.11.16 |
俄羅斯科學院-太平洋生物有機化學研究所學者-Dr. Dmitry Lvovich Aminin學術交流。 |
30人 |
2. PI或博碩生前往國外合作學術單位研習情形
日期 |
活動名稱 |
參與人數 |
104 07 13 |
俄羅斯科學院-太平洋生物有機化學研討會 |
2人 |
106.12.22 |
赴美拜訪技轉藥廠(Seattle Genetics, Inc.)討論產學合作計畫(Ab-lock (Hinge))前驅抗體研究成果 |
10人 |
107 09 30 |
俄羅斯科學院-太平洋生物有機化學研討會 |
2人 |
107.4.30 |
PEGS: the essential protein engineering summit美國/波士頓 (BOSTON) 蛋白藥物開發學術會議 |
5人 |
3. 中心邀請國外重要學者來校研究指導或協同教學人數情形
日期 |
活動名稱 |
參與人數 |
103.06.25 |
首都醫科大學趙明院長與研究中心成員進行交流-研究生培養與實驗室管理 |
50人 |
104.03.19 |
生物標記暨生技藥物研發中心邀請重要學者蒞臨中心進行指導- 劉扶東 中研院院士、特聘研究員兼生醫所 所長 張子文 中研院基因體研究中心特聘研究員、過敏抗體藥物 Xolair 研發者... 賴博雄 生策會副執行長: EPO, G-CSF(Amgen)等主要產品開發者... |
30人 |
107.11.16 |
俄羅斯科學院-太平洋生物有機化學研究所學者-Dr. Dmitry Lvovich Aminin實驗室交流 如何從現有資源探索創新科學研究主題 |
50人 |
|
|
|
|
|
授權案號 |
機構 |
技術名稱 |
發明人 |
金額 |
(103)高醫專授字第002號 |
SEATTLE GENETICS,INC(SGEN) |
可屏蔽抗體活性的閉鎖器 |
鄭添祿;莊智弘;呂韻綺;莊國祥;林文瑋;陳怡如;謝元欽 |
135,985,399 |
(105)高醫研授字第003號 |
中華海洋生技股份有限公司 |
HI-Q小分子褐藻醣膠於大腸直腸癌上的輔助使用 |
蔡祥麟;王照元;戴志融 |
1,000,000 |
(106)高醫研讓字第001號 |
凌越生醫股份有限公司; |
穩定分泌豬瘟E2蛋白之生物方法 |
鄭添祿;鄭達駿;鄭凱文; |
800,000 |
(105)高醫材轉字第003號 |
凌越生醫股份有限公司; |
基因重組之豬瘟病毒E2蛋白 |
鄭添祿;鄭達駿;鄭凱文; |
140,000 |
(105)高醫材轉字第002號 |
凌越生醫股份有限公司; |
基因重組之豬瘟病毒E2蛋白 |
鄭添祿;鄭達駿;鄭凱文; |
140,000 |
1050009359 |
重慶富進、DBAItalia、Allergan Sales、 其他(如附件) |
3.3授權移轉收入 |
羅傅倫;鄭添祿;陳炳梅;莊國祥 |
4,045,009 |
1050011089 |
協和新藥、Nektar Therapeutics、 其他(如附件) |
6.3授權移轉收入
|
羅傅倫;鄭添祿;陳炳梅;莊國祥 |
3,929,813 |
1040004462
|
國家衛生研究院、Algorithme、其他(如附件) |
15-2b授權移轉收入
|
羅傅倫;鄭添祿;陳炳梅;莊國祥 |
420,946 |
N |
BioAgilytix Labs |
2B5授權移轉收入 |
羅傅倫;鄭添祿;陳炳梅;莊國祥 |
18,120 |
1030004847 |
Biocon、Protalix、 其他(如附件) |
Anti-PEG Samp1er授權移轉收入 |
羅傅倫;鄭添祿;陳炳梅;莊國祥 |
46,337 |
1030009934 |
DBA Ita1ia、Bio-Layer Pty. Limited |
Biotin-conjugated anti-PEG Samp1er授權移轉收入 |
羅傅倫;鄭添祿;陳炳梅;莊國祥 |
17,361 |
1050006802 |
Moderna、藥華醫藥、其他(如附件) |
c3.3-IgG授權移轉收入 |
羅傅倫;鄭添祿;陳炳梅;莊國祥 |
1,110,534 |
1030000068 |
WuXi AppTec (Shanghai)、Ambrx、其他(如附件) |
E11抗體授權移轉收入 |
羅傅倫;鄭添祿;陳炳梅;莊國祥 |
973,475 |
N |
Precision Bioservices、Translate Bio、 、其他(如附件) |
Hu-6.3授權移轉收入 |
羅傅倫;鄭添祿;陳炳梅;莊國祥 |
1,405,789 |
1040004462
|
D.B.A. Italia、Genentech、其他(如附件) |
IgG-biotin授權移轉收入 |
羅傅倫;鄭添祿;陳炳梅;莊國祥 |
97,248 |
1050002848
|
Leidos Biomedical Researech、Biosensor Tools、其他(如附件) |
IgG授權移轉收入
|
羅傅倫;鄭添祿;陳炳梅;莊國祥 |
281,799 |
2019.03 更新
產學合作
計畫題目 |
時間 |
金額 |
主持人 |
合作單位 |
合作廠商 |
Hi-Q Fucoidam與Erbitux於大腸直腸癌治療的協同效果 |
105/10/01~ 107/09/30 |
4,280,136 |
王照元 |
臨床醫學研究所 |
中華海洋生技股份有限公司 |
一個先導性臨床試驗以評估放射治療的頭頸癌症患者,接受CSTC1-ACA疼痛紓解之有效性和安全性 |
104/04/01~ 105/11/30 |
1,232,250 |
黃旼儀 |
高雄醫學大學醫學系 |
儕陞生化技術股份有限公司 |
抗體鎖相關研究 |
104/01/01~ 106/12/30 |
10,000,000 |
鄭添祿 |
高雄醫學大學生物系 |
美國藥廠 |
EZH抗發炎的療效評估 |
103/11/01~ 104/10/31 |
250,000 |
黃旼儀 |
高雄醫學大學醫學系 |
儕陞生化技術股份有限公司 |
Hi-Q小分子褐藻醣膠於大腸直腸癌上的輔助使用 |
103/07/01~ 105/09/30 |
4,451,764 |
王照元 |
臨床醫學研究所 |
中華海洋生技股份有限公司 |
ACA癌症治療輔助用藥療效評估 |
103/06/01~ 106/05/31 |
1,050,000 |
黃旼儀 |
高雄醫學大學醫學系 |
儕陞生化技術股份有限公司 |
比較給予 tegafur-uracil 與觀察組用於根除性切除第三期大腸癌病患在使用過 oxaliplatin-based 輔助性治療後維持性療法之第三期隨機臨床試驗【計畫編號:KMUHIRB-F(I)-20160016】 |
2016/03/11~ 2024/02/29 |
4,500,000 |
王照元 |
臨床醫學研究所 |
東洋 |
優質疼痛管理病房計劃(GPM)於中度至重度癌症疼痛病患之照護型式及病患自陳式報告的效果評估 【計畫編號:KMUHIRB-F(II)-20160086】 |
|
|
王照元 |
臨床醫學研究所 |
台灣萌蒂藥品有限公司 |
一項多中心、隨機分配、開放式、3 組別第 3 期試驗,以 Encorafenib +Cetuximab 併用或未併用Binimetinib,與rinotecan/Cetuximab 或輸注 5-Fluorouracil 5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab 相比較,另加上 Encorafenib + Binimetinib + Cetuximab 的安全性引導治療,用於帶有BRAF V600E 突變的轉移性大腸直腸癌病患 【計畫編號:KMUHIRB-F(I)-20160120】 |
2017/1/01~ 2019/12/31 |
3,560,678 |
王照元 |
臨床醫學研究所 |
百瑞精鼎國際股份有限公司 |
一項使用 regorafenib 治療難治性晚期胃食道癌 (AGOC) 之隨機分組、第三期雙盲、安慰劑對照試驗 【計畫編號:KMUHIRB-F(II)-20160118】 |
2017/1/31~ 2019/7/31 |
4,810,040 |
王照元 |
臨床醫學研究所 |
Australian Gastro-Intestinal Trials Group (AGITG)、CRO: 台灣愛恩希科研股份有限公司 |
評估 Apatinib 加上最佳支持性照護(BSC)相較於安慰劑加上 BSC 使用於晚期或 轉移性胃癌(GC)病患之療效與安全性的一項前瞻性、隨機分配、雙盲、安慰劑對照、多國、 多中心、平行分組的第三期試驗 【計畫編號:KMUHIRB-F(I)-20170019】 |
2017/3/06~ 2019/12/31 |
2,489,285 |
王照元 |
臨床醫學研究所 |
晉加股份有限公司 |
野生型RAS基因之轉移性大腸直腸癌患者接受第一線Cetuximab治療中產生RAS抗藥性基因突變之多中心研究 【計畫編號:KMUHIRB-G(II)-20170027】 |
2017/10/31~ 2022/1/31 |
6,000,000 |
王照元 |
臨床醫學研究所 |
默克 |
2019.03 更新
Publications:
2008~2019 Publications2019.03 更新
2018 Publications
1. Huang MY, Lee HH, Tsai HL, Huang CW, Yeh YS, Ma CJ, Huang CM, Chen CY, Huang JJ, Wang JY(王照元). Comparison of efficacy and safety of preoperative Chemoradiotherapy in locally advanced upper and middle/lower rectal cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2018 Mar 27;13(1):53.
2. Chen YJ, Chen M, Hsieh YC(謝元欽), Su YC, Wang CH, Cheng CM, Kao AP, Wang KH, Cheng JJ, Chuang KH. Development of a highly sensitive enzyme-linked immunosorbent assay (ELISA) through use of poly-protein G-expressing cell-based microplates. Scientific Reports. 2018 Dec 14;8(1):17868.
3. Chang YT, Tsai HL, Kung YT, Yeh YS, Huang CW, Ma CJ, Chiu HC, Wang JY(王照元). Dose-Dependent Relationship Between Metformin and Colorectal Cancer Occurrence Among Patients with Type 2 Diabetes-A Nationwide Cohort Study. Translational Oncology. 2018 Apr;11(2):535-541.
4. Yao TC, Chung RH, Lin CY, Tsai PC, Chang WC(張偉嶠), Yeh KW, Tsai MH, Liao SL, Hua MC, Lai SH, Chen LC, Chang SW, Yu YW, Hsu JY, Chang SC, Cheng WC, Hu D, Hong X, Burchard EG, Wang X, Tzeng JY, Tsai HJ, et al. Genetic loci determining total immunoglobulin E levels from birth through adulthood. Allergy. 2018 Oct 31.
5. Li CC, Tsai HL, Huang CW, Yeh YS, Tsai TH, Wang JY(王照元). Iatrogenic pseudoaneurysm after bevacizumab therapy in patients with metastatic colorectal cancer: Two case reports. Molecular and Clinical Oncology. 2018 Nov;9(5):499-503.
6. Liao JM, Wang YT(王焰增). In silico studies of conformational dynamics of Mu opioid receptor performed using gaussian accelerated molecular dynamics. Journal of Biomolecular Structure and Dynamics. 2018 Jan 7:1-12
7. Lu HF, Wong HS, Chen BK, Liao HT, Hsu YW, Ikegawa S, Cho EC, Hung KS, Chang WC(張偉嶠). Integrative genomic analysis for the functional roles of ITPKC in bone mineral density. Bioscience Reports 2018 Nov 30;38(6).
8. Ho KH, Chang CK, Chen PH, Wang YJ(王照元), Chang WC, Chen KC. miR-4725-3p targeting stromal interacting molecule 1 signaling is involved in xanthohumol inhibition of glioma cell invasion. Journal Of Neurochemistry. 2018 Aug;146(3):269-288
9. Hsieh YC(謝元欽), Wang HE, Lin WW, Roffler SR, Cheng TC, Su YC, Li JJ, Chen CC, Huang CH, Chen BM, Wang JY, Cheng TL, Chen FM. Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes. Theranostics. 2018 May 9;8(11):3164-3175.
2017 Publications
1. Chang CJ, Chen CH, Chen BM, Su YC, Chen YT, Hershfield MS, Lee MM, Cheng TL(鄭添祿), Chen YT, Roffler SR, Wu JY. A genome-wide association study identifies a novel susceptibility locus for the immunogenicity of polyethylene glycol. nature communications 2017 Sep 12;8(1):522
2. Huang CM, Huang MY, Tsai HL, Huang CW, Ma CJ, Lin CH, Huang CJ, Wang JY(王照元). A retrospective comparison of outcome and toxicity of preoperative image-guided intensity-modulated radiotherapy versus conventional pelvic radiotherapy for locally advanced rectal carcinoma. Journal of Radiation Research 2017 Mar 1;58(2):247-259
3. Huang B(黃斌), Cheng JK, Wu CY, Chen PH, Tu PS, Fu YS, Wu CH. Camptothecin promotes the production of nitric oxide that triggers subsequent S-nitrosoproteome-mediated signaling cascades in endothelial cells. Vascul Pharmacol 2017 Mar;90:27-35.
4. Su YC, Burnouf PA, Chuang KH, Chen BM, Cheng TL(鄭添祿), Roffler SR. Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy. nature communications 2017 Jun 8;8:15507
5. Huang YH, Yang KD, Hsu YW, Lu HF, Wong HS, Yu HR, Kuo HC, Huang FC, Lo MH, Hsieh KS, Chen SF, Chang WC(張偉嶠), Kuo HC. Correlation of HAMP gene polymorphisms and expression with the susceptibility and length of hospital stays in Taiwanese children with Kawasaki disease. Oncotarget 2017 May 8;8(31):51859-51868.
6. Chang LS, Hsu YW, Lu CC, Lo MH, Hsieh KS, Li SC, Chang WC(張偉嶠), Kuo HC. CYP2E1 Gene Polymorphisms Related to the Formation of Coronary Artery Lesions in Kawasaki Disease. Pediatric Infectious Disease. 2017 Nov;36(11):1039-1043
7. Huang CW, Chen YT, Tsai HL, Yeh YS, Su WC, Ma CJ, Tsai TN, Wang JY(王照元). EGFR expression in patients with stage III colorectal cancer after adjuvant chemotherapy and on cancer cell function. Oncotarget. 2017 Dec 9;8(70):114663-114676
2016 Publications
- Prijovich ZM, Burnouf PA, Chou HC, Huang PT, Chen KC,Cheng TL, Leu YL, Roffler SR.Synthesis and Antitumor Properties of BQC-Glucuronide, a Camptothecin Prodrug for Selective Tumor Activation.Mol Pharm. 2016 Apr 4;13(4):1242-50.
- Huang WC, Burnouf PA, Su YC, Chen BM, Chuang KH, Lee CW, Wei PK,Cheng TL*, Roffler SR*.Engineering Chimeric Receptors To Investigate the Size- and Rigidity-Dependent Interaction of PEGylated Nanoparticles with Cells.ACS Nano. 2016 Jan 26;10(1):648-62.
2015Publications
- Huang CC, Kuo KK, Cheng TC, Chuang CH, Kao CH, Hsieh YC, Cheng KH, Wang JY, Cheng CM, Chen CS,Cheng TL*.Development of Membrane-Bound GM-CSF and IL-18 as an Effective Tumor Vaccine.PLoS One. 2015 Jul 17;10(7):
- Cheng TC, Pan CH, Chen CS, Chuang KH, Chuang CH, Huang CC, Chu YY, Yang YC, Chu PY, Kao CH, Hsieh YC,Cheng TL*.Direct coating of culture medium from cells secreting classical swine fever virus E2 antigen on ELISA plates for detection of E2-specific antibodies.Vet J. 2015 Jul;205(1):107-9.
- Tung HY, Su YC, Chen BM, Burnouf PA, Huang WC, Chuang KH, Yan YT,Cheng TL, Roffler SR.Selective Delivery of PEGylated Compounds to Tumor Cells by Anti-PEG Hybrid Antibodies.Mol Cancer Ther. 2015 Jun;14(6):1317-26.
- Cheng TC, Chuang KH, Roffler SR, Cheng KW, Leu YL, Chuang CH, Huang CC, Kao CH, Hsieh YC, Chang LS,Cheng TL*, Chen CS*. Discovery of specific inhibitors for intestinal E. coli β-glucuronidase through in silico virtual screening.
- Hsieh YT, Chen KC, Cheng CM, Cheng TL, Tao MH, Roffler SR. Impediments to Enhancement of CPT-11 Anticancer Activity by E. coli Directed Beta-Glucuronidase Therapy.PLoS One. 2015 Feb 17;10(2):e0118028.
- Changchien JJ, Chen YJ, Huang CH, Cheng TL, Lin SR, Chang LS. Quinacrine induces apoptosis in human leukemia K562 cells via p38 MAPK-elicited BCL2 down-regulation and suppression of ERK/c-Jun-mediated BCL2L1 expression.Toxicol Appl Pharmacol. 2015 Apr 1;284(1):33-41
2014 Publications
- Su YC, Cheng TC, Leu YL, Roffler SR, Wang JY, Chuang CH, Kao CH, Chen KC, Wang HE, Cheng TL*.PET Imaging of β-Glucuronidase Activity by an Activity-Based 124I-Trapping Probe for the Personalized Glucuronide Prodrug Targeted Therapy.Mol Cancer Ther. 2014 Dec;13(12):2852-63. 2013 IF=6.107 (23/202=11.38 in ONCOLOGY.
- Chien-Han Kao, Jaw-Yuan Wang, Kuo-Hsiang Chuang, Chih-Hung Chuang, Ta-Chun Cheng, Yuan-Chin Hsieh, Yun-long Tseng, Bing-Mae Chen, Steve R. Roffler, Tian-Lu Cheng*. One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles.Biomaterials. 2014 Dec;35(37):9930-40. 2013 IF=8.312 (2/77=2.5%) in ENGINEERING, BIOMEDICAL.
- Kuo-Hsiang Chuang,Chien-Han Kao,Steve R. Roffler,Ssu-Jung Lu,Ta-Chun Cheng, Yun-Ming Wang,Chih-Hung Chuang,Yuan-Chin Hsieh,Yeng-Tseng Wang,Jaw-Yuan Wang,Kuo-Yi Wengand Tian-Lu Cheng*. Development of an Anti-Methoxy Poly(ethylene glycol) (α-mPEG) Cell-Based Capture System to Measure mPEG and mPEGylated Molecules. Macromolecules.2014, 47, 6880−6888.2013 IF=5.927 (3/82, 3.7%) in POLYMER SCIENCE.
- Kuo-Hsiang Chuang, Yuan-Chin Hsieh, I-Shiuan Chiang, Chih-Hung Chuang, Chien-Han Kao, Ta-Chun Cheng, Yeng-Tseng Wang, Wen-Wei Lin, Bing-Mae Chen, Steve R. Roffler, Ming-Yii Huang, Tian-Lu Cheng*. High-Throughput Sorting of the Highest Producing Cell via a Transiently Protein-Anchored System.PLoS One. 2014 Jul 18;9(7):e102569. 2013 (8/55=14.5% in MULTIDISCIPLINARY SCIENCES
- Cheng CM, Tzou SC, Zhuang YH, Huang CC, Kao CH, Liao KW, Cheng TC, Chuang CH, Hsieh YC, Tai MH, Cheng TL*. FunctionalproductionPLoS One. 2014 May 13;9(5):e97367.2013 (8/55=14.5% in MULTIDISCIPLINARY SCIENCES
- Chen YJ, Lin HC, Chen KC, Lin SR, Cheng TL, Chang LS. Taiwan cobra phospholipase A2 suppresses ERK-mediated ADAM17 maturation, thus reducing secreted TNF-α production in human leukemia U937 cells.Toxicon. 2014 May 27;86C:79-88.
- Su YC, Al-Qaisi TS, Tung HY, Cheng TL, Chuang KH, Chen BM, Roffler SR. Mimicking the germinal center reaction in hybridoma cells to isolate temperature-selective anti-PEG antibodies.MAbs. 2014 May 14;6(4).
- Chuang CH, Wang WJ, Li CF, Ko CY, Chou YH, Chuu CP, Cheng TL*, Wang JM*. The combination of the prodrugs perforin-CEBPD and perforin-granzyme B efficiently enhances the activation of caspase signaling and kills prostate cancer.Cell Death Dis. 2014 May 8;5:e1220.2013 IF=5.177 (49/185=26.5%) in CELL BIOLOGY.
- Chen YJ, Wu SC, Chen CY, Tzou SC, Cheng TL, Huang YF, Yuan SS, Wang YM. Peptide-based MRI contrast agent and near-infrared fluorescent probe for intratumoral legumain detection.
2013 publications
- Cheng TC, Chuang KH, Chen M, Wang HE, Tzou SC, Su YC, Chuang CH, Kao CH, Chen BM, Chang LS, Roffler SR, Cheng TL*.Sensitivity of PEGylated interferon detection by anti-polyethylene glycol (PEG) antibodies depends on PEG length.Bioconjug Chem.2013 Aug 21;24(8):1408-13.2013 IF=4.821 (7/58=12.1%) in CHEMISTRY, ORGANIC
- Liu WH, Chen YJ, Cheng TL, Lin SR, Chang LS.Cross talk between p38MAPK and ERK is mediated through MAPK-mediated protein phosphatase 2A catalytic subunit α and MAPK phosphatase-1 expression in human leukemia U937 cells.Cell Signal. 2013 Sep;25(9):1845-51
- Chen SH, Kuo YT, Cheng TL, Chen CY, Chiu YY, Lai JJ, Chang CC, Jaw TS, Wang YM, Liu GC.In vivo magnetic resonance imaging of mice liver tumors using a new gadolinium-based contrast agent. Kaohsiung J Med Sci. 2013 May;29(5):246-53.
- Cheng CM, Chen FM, Lu YL, Tzou SC, Wang JY, Kao CH, Liao KW, Cheng TC, Chuang CH, Chen BM, Roffler S,Cheng TL*.Expression of β-glucuronidase on the surface of bacteria enhances activation of glucuronide prodrugs.Cancer Gene Ther. 2013 May;20(5):276-81. 2013 IF=2.553 (58/165=35.2%) in BIOTECHNOLOGY & APPLIED MICROBIOLOGY.
- Wu SC, Lin KL, Wang TP, Tzou SC, Singh G, Chen MH, Cheng TL, Chen CY, Liu GC, Lee TW, Hu SH, Wang YM.Imaging specificity of MR-optical imaging agents following the masking of surface charge by poly(ethylene glycol). 2013 May;34(16):4118-27.
- Lu CY, Tsai HL, Uen YH, Hu HM, Chen CW, Cheng TL, Lin SR, Wang JY. Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer.Br J Cancer. 2013 Mar 5;108(4):791-7.